Glycation of immunoglobulin G (IgG) can result from incubation with a reducing sugar in vitro or during circulation in vivo. Upon injection of a recombinantly produced human therapeutic IgG into humans, changes in the glycation levels could be observed as a function of circulation time. Mass changes on the individual IgG polypeptide chains as the results of glycation were determined using reversed-phase liquid chromatography/mass spectrometry. Changes to the light and heavy chains were low but easily detectable at 0.00092 and 0.0021 glucose (Glc) additions per chain per day, respectively. Levels of glycation found on the Fc portion of IgG isolated from healthy subjects, using a similar analytical approach, were on average 0.045 Glc molecules per fragment. In vivo glycation rates could be approximated in vitro by modeling the physiological glycation reaction with a simplified incubation containing physiological Glc concentrations, pH and temperature but with a high concentration of a single purified IgG. To test the impact of glycation on IgG function, highly glycated IgG1 and IgG2 were prepared containing on average 42-49 Glc molecules per IgG. Binding to FcγIIIa receptors, neonatal Fc receptor or protein A was similar or identical to the non-glycated IgG controls. Although the modifications were well distributed throughout the protein sequence, and at high enough levels to affect the elution position by size-exclusion chromatography, no changes in the tested Fc functions were observed.
Introduction
Glycation is a type of non-enzymatic glycosylation, in which a protein is modified by a reducing sugar. The reaction occurs between a primary amine on the protein, either the lysine (Lys) side-chain epsilon amino group or the α-amino N-terminus (Holmquist and Schroeder 1964; Garlick and Mazer 1983; Shilton and Walton 1991) , and the carbonyl carbon of the sugar to form a Schiff base, as illustrated in Figure 1 (Bunn and Higgins 1981) . This unstable aldimine linkage can then rearrange to form a ketoamine (Bucola and Cerami 1992) . Although the ketoamine linkage is considerably more stable than the aldimine linkage, it has been shown to be slowly broken under relatively mild conditions (Acharya and Sussman 1984; Miller et al. 2011) . Both the aldimine and ketoamine products can be converted to more stable products with the addition of a reducing reagent, such as sodium borohydride (Baynes et al. 1984) . Oxidation and further rearrangement of the ketoamine and aldimine products can generate a collection of stable adducts known as advanced glycation end products or AGEs (Bucola and Cerami 1992; Cho et al. 2007) . Although glycation occurs naturally on proteins in vivo, the level may increase in certain disease states. For example, in diabetes, elevated blood Glc concentrations result in increased hemoglobin (Koenig et al. 1976) , albumin (Austin et al. 1987 ) and immunoglobulin G (IgG) glycation (Austin et al. 1987; Kaneshige 1987; Lapolla et al. 2000) . Increases in AGE have been associated with other diseases as well, including rheumatoid arthritis (Ligier et al. 1998; Tai and Newkirk 2000) . The primary sites of glycation have been analyzed for a number of proteins under a variety of conditions. On some proteins, the N-terminus (Holmquist and Schroeder 1964) or specific Lys (Zhang et al. 2008; Miller et al. 2011 ) are modified to a much greater degree than other sites, indicating sequence or structural specificity to the reaction. In general, it appears that the pKa and exposure of the amine attachment site determines the degree of Schiff base formation, and the proximity of amino acids capable of proton abstraction helps catalyze the formation of the ketoamine products (Venkatraman et al. 2001; Zhang et al. 2008) . Buffer components that can bind near the reaction site and abstract protons, such as phosphate, can also serve to increase the formation of stable products (Watkins et al. 1987) . Thus, the sequence, reaction conditions and what glycation product is being measured can all affect the degree of glycation and the site specificity of the reaction.
Recombinant therapeutic antibodies are typically expressed in Chinese hamster ovary (CHO) cells and secreted, where they can be glycated by the Glc in the media. As the protein sequence differs between therapeutic antibodies, the degree of glycation would also be expected to differ, even under similar cell culture conditions (Zhang et al. 2008; Miller et al. 2011 ). Differences in cell culture length, expressed monoclonal antibody (mAb) concentration and the Glc concentration in the media feeds would also be expected to impact glycation levels. Minimizing and controlling glycation, or other posttranslational modifications, is warranted when the safety or efficacy of the drug is impacted. Forced glycation studies using high pH conditions have shown that Fc functions of human antibodies, such as protein A binding and complement activation, can be impaired (Dolhofer-Bliesener and Gerbitz 1990) . Antibody binding to its target also has the potential to be impacted by glycation, but the effect will depend on the protein sequence in and around the variable complementarity determining region, which varies among antibody molecules.
In this study, we have followed the glycation reaction on endogenous and recombinant human antibodies, both in vitro and in vivo. The contributions to total glycation from the labile aldimine and more stable ketoamine forms were separately monitored via the selective use of sodium borohydride reduction. Since the Fab protein sequence, and therefore glycation susceptibility to Fab function, differs between antibodies, we have focused primarily on the conserved Fc regions. An attempt was made to model physiological glycation rates observed using a simple in vitro system. The impact of Fc glycation on function was also explored using surrogate binding assays that probed the interaction between mAbs and FcγRIIIa, neonatal Fc receptor (FcRn) and immobilized protein A.
Results and discussion
Glycation quantification on large molecules can be determined through LC/MS analysis by determining the portion of the deconvoluted spectrum with an increased mass of 162 Da, or multiples of that mass change, over the base mass (Gadgil et al. 2007) . Glycation values obtained are, of course, dependent on these adducts surviving the sample preparation and analysis. Concern that lability of glycation linkages may result in underestimation of this modification led us to evaluate how sample preparation impacted the IgG glycation values measured. In initial experiments, native mAbA was gently prepared through rapidly desalting, then analyzed in-line with an electrospray ionization (ESI)-TOF mass spectrometer. Although the deconvoluted mass spectrum displays multiple peaks differing by the expected 162 Da (Figure 2A, top) , not all of these changes could be attributed to glycation. In addition to glycation heterogeneity, mAbA displayed Fc N-linked glycan heterogeneity. The two major glycan forms G0F and G1F differ by a single galactose residue, which also generates a 162 Da difference. Thus, this mass difference alone cannot distinguish glycosylation differences from glycation differences. However, changes to the spectrum as the result of incubation with Glc for 7 days can be fully attributed to glycation (Figure 2A, bottom) . Using this change in glycation, or hexose index (Gadgil et al. 2007 ), a time course of in vitro glycation can be plotted ( Figure 2B , top). The slope of this plot provides the initial, linear rate of glycation under these conditions, of 0.039 Glc/IgG/day (R 2 = 0.97). Additional sample preparation steps were tested for enhancement of glycation analysis precision and for their impact to sensitivity. Glycation of mAbA after the enzymatic removal of the N-linked glycan generated a similar glycation rate (0.059 Glc/IgG/day, R 2 = 0.81) to the untreated sample, but did not appear to improve the spectral quality with respect to precision or sensitivity. Reduction and disassembly of the antibody followed by reversed-phase HPLC allowed glycation analyses of the HC and LC separately. Deconvoluted mass spectra of the HC and LC are shown in Figure 2C and E, respectively. The smaller masses of the individual polypeptide chains ( 45 kDa for HC and 23 kDa for LC) when compared with the mass of the assembled antibody ( 147 kDa) improved the resolution of the base mass from the glycated masses. However, this resolution improvement is somewhat offset by the decrease in sensitivity. Disassembly of the antibody into its individual polypeptide chains also reduced the glycation signal strength by dividing it among the four chains. Comparison of the various samples indicates that LC glycation generated better quality spectra, but individual analysis of both the LC and HC produced glycation time course results of acceptable quality ( Figure 2D and F). Mathematical reconstruction of the whole mass glycation time course (rate) by adding the individual chain rates together and multiplying by 2 (i.e. for 2 HC + 2 LC) suggests that the sample treatments shown did not result in significant loss of the glycation signal. For subsequent analyses, antibody deglycosylation and reduction followed by RP-HPLC/MS and mathematical reconstruction of the whole mass glycation were used to measure antibody glycation. Glycation of therapeutic antibodies in vivo was obtained by affinity isolation of the protein from serum obtained at defined times after an intravenous injection into human subjects. As shown in Figure 3A and B, glycation changes over time in vivo could be measured, with the mAbA LC glycation rates of 0.00092 Glc/LC per day and HC rates of 0.0021 Glc/HC per day. These rates are approximately proportional to the size and Lys content of each chain and suggest that average Lys glycation rates are similar between the chains. More scatter was present in the HC plots (R 2 = 0.65) than the LC plots (R 2 = 0.88), possibly due to the better resolution of the LC spectra. On some sample sets, sodium borohydride was added to the serum samples prior to the isolation of the antibody protein to test whether the reduction in the aldimine and/or the ketoamine (Figure 1 ) better preserved the attached Glc. No measurable differences in the glycation levels were observed when analyzing LC ( Figure 3A , sets III and IV vs sets III + NaBH 4 and IV + NaBH 4 ). Glycation was also measured on endogenous human antibodies isolated from human subjects. The polyclonal nature of antibodies, which results in a large collection of antibodies differing in mass, precludes the use of LC, HC or assembled Glycation in vivo molecular mass analyses, as performed on mAbA. Instead, glycation was measured on the conserved Fc portion of endogenous polyclonal antibodies isolated from healthy human subjects, by the use of papain fragmentation. Analysis was limited to the most prevalent IgG1 subtype. Results shown in Table I indicate that the glycation of IgG1 Fc is found naturally, at levels ranging from 0.037 to 0.061 Glc/Fc, with an average of 0.045 Glc/Fc. Assuming for the average antibody that glycation levels on Fc and Fab fragments were similar, endogenous antibodies (2Fab + Fc) would carry 0.13 Glc/antibody, or 13% of the antibody is glycated. How does this value compare with the glycation rates measured on the therapeutic antibody? If the endogenous antibody glycation level represents the steady-state level at the clearance half life of 23 days (Out et al. 1984; Vlug et al. 1994; Alyanakian et al. 2003) , then one can calculate the projected glycation level of mAbA at this time point. Mathematical reassembly of the antibody mAbA 23 days after injected predicts (2 HCs × 23 days × 0.0021 Glc/HC/day) + (2 LCs × 23 days × 0.0009 Glc/LC/day) = 0.138 Glc/mAbA, or 14% of the antibody is glycated. Thus, glycation rates observed for the therapeutic antibody in vivo are consistent with the expected glycation levels observed among endogenous antibodies.
A series of experiments were performed to model the in vivo glycation of antibodies through in vitro incubation reactions. Replicate samples collected at each time point were treated either with borohydride, to reduce both aldimine and ketoamine to stable, quantifiable glycation products with mass additions of 164 Da, or with hydroxylamine, to ensure the complete reversal of aldimine and measure only ketoamine (Venkatraman et al. 2001) . In an initial experiment, shown in Figure 4 , mAbA (20 mg/mL) incubated with 0.5 M Glc displayed reaction profile differences in the borohydride reduced vs the unreduced samples, for both LC and HC. The time course plot for the reduced samples displayed a steeper initial rise in product formation than the unreduced samples. Subtraction of the unreduced (ketoamine products) values from the borohydride-treated ones generated the time course of the aldimine (Schiff base) formation (Baynes et al. 1984) . Ketoamine formation clearly lags behind aldimine formation, as addition of a reducing reagent increased the total amount of product measured. Other mAbs showed, in general, similar time course profiles but with some differences in rates of HC and LC glycation, attributable to sequence differences among these proteins (data not shown).
In a second experiment, mAbA was incubated in normal human serum at 200 μg/mL (approximating the high end of the concentration range studied with clinical samples), with an additional 250 mM Glc. This experiment was conducted to measure glycation rates in serum with high Glc concentrations but otherwise physiological conditions. These conditions produce more easily quantifiable glycation rates that can be used to calculate kinetic rate constants. The results showed behavior similar to that shown in Figure 4 , albeit with slower kinetics (data not shown). If one uses a simplified view of serum consisting only of 40 mg/mL human serum albumin (HSA) and 10 mg/mL IgG (Vlug et al. 1994) , and using the known Lys content of HSA and assuming a Lys content for serum IgG similar to mAbA (88 Lys/mol), serum would contain 40 mM Lys residues, a significant excess over the expected Glc concentration (4.1-5.5 mM in healthy subjects; Sacks 2008) . A low mAbA concentration (200 µg/mL; equivalent to 0.1 mM Lys) spiked into such a milieu can be expected to exhibit decreased relative glycation rates (relative glycation on mAbA) due to the large excess of serum protein Lys competing for the limited Glc reactants.
In a third modeling experiment, mAbA at 69.1 mg/mL in PBS ( pH 7.4) was incubated with various Glc concentrations at 37°C ( Figure 5 ). This mAb concentration was chosen to approximate the total serum protein Lys concentration, again assuming serum consists only of 40 mg/mL albumin and 10 mg/mL endogenous IgG. This model ignores the Lys content of other, less abundant serum proteins as well as the glycation potential of low-molecular-weight amines present in serum. This approach also assumes that the average Lys reactivity of large proteins such as IgG and HSA is similar, even though AM Goetze et al.
we acknowledge that wide reactivities at individual positions can occur. The obvious advantage of this approach is that relative glycation rates are modeled using the single protein of interest, obviating the need to affinity purify samples from complex mixtures. In addition, high Glc levels can be chosen to enhance the analytical sensitivity and consequently the accuracy of observed rates. Kinetic rate constants were calculated from all three models using the following reaction scheme:
where Lys is the lysine, AL the aldimine and KA the ketoamine. The rate constant for the ketoamine breakdown is assumed to be small (Acharya and Sussman 1984; Baynes et al. 1984) , so was ignored. The forward rate constant in the ketoamine formation, k 2 , was obtained from the following expression:
where [AL] EQ represents the aldimine concentration at equilibrium, which is readily determined from the difference between the glycation time course profiles with and without borohydride treatment (Figure 4 ) by multiplying the aldimine ratio per chain times the Lys content per chain. In these Total glycation" was determined after borohydride reduction, "ketoamine" after incubation with hydroxylamine, "aldimine" is mathematical difference between "total glycation" and "ketoamine". Insets, details of early time points. The day 6 time point for HC total glycation is omitted as it could not be reliably quantified due to low signal-to-noise ratio. Incubation conditions used were: 20 mg/mL of mAbA in 30 mM NaHCO 3 , 100 mM NaCl, pH 8, buffer incubated with 0.5 M Glc at 37°C. 
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equations, aldimine and ketoamine concentrations refer to the total absolute concentrations of these products (i.e. total concentration of Lys × fraction of Lys modified). Table II summarizes the k 2 rate constants for average LC Lys and average HC Lys separately from the three model experiments outlined above (labeled "in vitro", "in serum" and "physiological model", respectively, in Table II ). Although the experimental conditions for the three reactions differ significantly with respect to mAb and Glc concentrations, buffer composition and the presence or the absence of competing substrate proteins, similar rate constants were calculated from each experiment. Having a reliable estimate for k 2 allows the calculation of the rate of ketoamine formation under physiological conditions. The fact that this rate constant for an average mAbA Lys is similarly independent of the presence or the absence of an 400-fold excess of competing Lys from serum proteins (largely HSA; compare "in serum" with "physiological model", Table II ) validates our assumption that the average Lys reactivity of proteins, the size of HSA or IgG, is likely to be very similar with respect to glycation. In addition, the consistency of the k 2 rate constants in Table II does not suggest a strong dependence on exact buffer conditions in the vicinity of physiological pH. Total glycation levels at time points beyond that required to achieve aldimine equilibrium ( 2 h) are the sum of the equilibrium aldimine concentration and the accumulating ketoamine concentration. Thus, beyond the time necessary to achieve aldimine equilibrium, its fractional contribution to total glycation decreases with time. Extrapolating the reaction rate (Figure 4) to the 20-60 days time window, in which most of the in vivo data were collected (Figure 3) , projects little expected difference between the ketoamine concentration and the total glycation concentration. Figure 5 demonstrates that glycation rates using LC as an example in our physiological model are linear with respect to Glc concentrations up to at least 0.5 M. The linear equation of this simple model, utilizing only a single protein, can then be used to calculate glycation rates in a much more complex milieu (blood) and at lower Glc concentrations, which would otherwise present analytical challenges. Using the linear regression equations from the physiological model (the LC regression is shown in Figure 5 ), we calculate 0.0022 Glc/day for mAbA LC assuming 6 mM Glc in vivo, whereas a rate of 0.0010 ± 0.0001 Glc/LC/day (n = 4) was observed. For mAbA HC, we calculate a rate of 0.0023 Glc/day vs a less reliably (due to increased scatter in the rate data as a result of less accurate deconvolution) measured rate ( Figure 3B ) of 0.0020 ± 0.0008/day (n = 4). While the physiological model approximates the serum protein content as consisting of only albumin and IgG at concentrations of 40 and 10 mg/mL, respectively, this is an acknowledged oversimplification. These two proteins constitute only 70% of serum protein mass (Silva et al. 2006) and, in addition, concentrations of both of these proteins can vary among individual subjects (Vlug et al. 1994) . Furthermore, free amino acids (McMenamy et al. 1957 ) and other low-molecular-weight amines may also scavenge Glc. For these reasons, it seems likely that our simplified physiological model overestimated glycation rates perhaps by a factor of close to 2, providing a reasonable explanation for the discrepancy with the more accurately (compared with HC) determined in vivo glycation rate of mAbA LC. A more refined model, however, seems unwarranted in view of the unknown, and fluctuating, concentrations of key glycation reactants in individual clinical subjects.
Highly glycated mAbs (HG-mAbs) were generated to test the consequences of glycation on Fc function. Two mAbs were incubated with high Glc concentrations (2 M) but under otherwise physiological conditions ( pH 7.4 at 37°C) for extended periods of time (up to 23 days) to promote the glycation of the reactive Lys. Incubations in 2 M sorbitol under similar conditions served as controls. Under these conditions, mAbA (IgG2) contained on average 42 Glc/antibody (for an average of 0.48 Glc/Lys) and mAbC (IgG1) contained 49 Glc/ antibody (average 0.54 Glc/Lys). Total glycation was computed as the sum of the glycation levels measured by whole mass analysis of proteolytic fragments (half Fc, LC and Fd). For both mAbs, all three fragments showed similar degrees of glycation when normalized for Lys content of each fragment (data not shown). Peptide mapping was performed on the HG-mAbs to determine the glycation modification sites. Because glycation modification can inhibit proteolytic cleavage for enzymes recognizing Lys residues, such as Lys-C or trypsin, AspN protease was used to analyze these samples. The extracted ion current MS peak height was compared for all base and modified (+n × 162 Da) peptides, using all charge states available, to determine the percentage of modification for all Lys-containing peptides. As shown in Table III , the reactivity of the Fc Lys varied, from 0% at Lys 409 to nearly full glycation of Lys 246/248 for IgG1. Multiple Lys residues in the Fc, as well as other portions of the molecules, gave clear evidence of being partially modified with two Glc molecules as demonstrated by glycation distributions for individual peptides that included peptides with more than one Glc per Lys. Glycation levels of Lys 246/248 differed significantly between IgG1 and IgG2, possibly because the corresponding AspN peptide includes the hinge region, which differs significantly in structure between the isotypes (Jefferis 2007) . Antibody-dependent cellular cytotoxicity (ADCC) is considered to be an important function of both endogenous polyclonal IgG1 as well as some therapeutic monoclonal IgG1 proteins. ADCC is triggered when an IgG1 molecule simultaneously engages both a target cell, by binding to surface ligands via its antigen-combining sites, and a leukocyte effector cell by binding to Fc receptors (FcγR) via its Fc domain. Binding of monomeric IgG1 to soluble FcγRIIIa in solution has been used as a surrogate binding assay to measure IgG1 Fc effector function required to carry out ADCC in vivo (Masuda et al. 2007 ). Binding of HG-mAbC and the sorbitol-incubated mAbC control to FcγRIIIa was determined by a competitive in vitro AlphaScreen assay. The results, shown in Figure 6 , show no significant difference (less than expected 20% assay variability) in the binding curves between these two samples. In a systematic mutation analysis, replacement of Lys322 or Lys338 to Ala was previously shown to decrease affinity for FcγIIIa binding (Shields et al. 2001 ). In our peptide map analysis of mAbC, IgG1, these two Fc Lys occur in a peptide containing seven Lys with an average peptide glycation level of 2.9 Glc/peptide (Table III) . While this leads to a calculation of an average glycation content of 0.41 Glc/Lys within this peptide, we cannot provide more definitive information concerning glycation levels of the two Lys in question. Nevertheless, it is clear that glycation of Lys in this peptide to an average level of 0.41 Glc/Lys, and to an average level of 0.5 Glc/Lys for the Fc overall, did not measurably affect binding to FcγRIIIa; presumably, ADCC activity is unaffected as well.
The FcRn increases the circulating half life of antibodies through a salvage pathway. Binding between the Fc and the receptor is stronger at low pH conditions, such as those found in the endosome, and weaker under the neutral pH conditions found in the blood. HG-mAbA and HG-mAbC affinity to recombinant soluble human FcRn was tested at pH 6, using a competitive binding assay. Results, shown in Figure 7 , show no significant difference in the binding curves between the HG-mAb samples and the sorbitol controls. Modification at residues Lys 248 and Lys 288 are of special concern, since these are known to interact indirectly with FcRn (Shields et al. 2001; Liu, Pop et al. 2008) . From the AspN-reduced peptide mapping results, significant levels of glycation are predicted at both of these sites, although in each case the peptide map resolution and MS/MS data cannot clearly differentiate between glycation at Lys 246 and Lys 248 or between glycation at Lys 288 and Lys 290. Some quantitative conclusions can be reached regarding the specific glycation levels of Lys 246 and Lys 288, however. The AspN peptide containing Lys 288 and Lys 290 was present as monoglycated (15%), diglycated (53%) and triglycated (32%) forms. This places a lower bound of 32% on the proportion of Lys 288 that must be glycated; in reality, this number is likely much higher. For similar reasons, by examining the AspN peptide containing Lys 246 and Lys 248, Lys 248 must be minimally 12% glycated. In summary, it is likely that both Lys 248 and Lys 288, which indirectly contact FcRn, are glycated sufficiently to expect an effect on FcRn binding to be measurable. However, it appears that these Lys, as well as others on the Fc, can accommodate glycation without measurably perturbing affinity for this receptor. One possible explanation is that these Lys residues provide longer range charge interactions with FcRn, and, since the Lys positive charge is preserved after glycation, no effect on binding is apparent. Based on our results, we expect no changes in the in vivo clearance of HG-mAbs via FcRn-dependent mechanisms. The in vivo half of mAbA under the conditions shown in Figure 3 is 26 days; we have no information on whether glycation might affect mAb clearance by another mechanism.
The impact of glycation on protein A binding was tested by injection of the HG-mAbA and HG-mAbC onto a protein A affinity column and eluting with a pH gradient. This approach has previously been used to demonstrate that oxidation of two Fc methionines weakens antibody protein A affinity (Pan et al. 2009 ). Results from these experiments are shown in Figure 8 . The major peak of unmodified mAbA (IgG2) sample eluted at 13.3 min and a minor peak, previously shown to contain oxidized Fc methionines, eluted at 11 min ( Figure 8A , top chromatogram). A similar profile was observed for the mAbC 
(IgG1) sample, though shifted to later eluting positions (17.6 min for the major peak in Figure 8B , top chromatogram). Increases in the minor peak area were observed for both heavily glycated mAbs, but were similar in magnitude to the sorbitol incubation control, suggesting that this change was the result of methionine oxidation, not glycation (bottom chromatograms in Figure 8A and B for mAbA and mAbC, respectively). For both HG-mAbA and HG-mAbC, a slight shift in the elution position to earlier retention times was observed, but this was not observed with the sorbitol controls. These results suggest that Fc glycation had a small but measurable impact on protein A elution affecting 100% of each mAb population. A reasonable explanation for this was found by examining the SEC behavior of the highly glycated and sorbitol-incubated control samples. Sorbitol-incubated mAbs eluted with retention times similar to those of reference standards (16.0 min), whereas HG-mAbs eluted at 15.5 min, distinct from small amounts of dimer eluting at 13.5 min ( Figure 8C and D for mAbA and mAbC, respectively). HG-mAbs exhibit a larger hydrodynamic radius, consistent with the addition of an average of 45 Glc residues. The slightly earlier elution of the HG-mAb during protein A interaction chromatography can be explained by its larger size impeding access to the interstices of the protein A resin.
Conclusions
Using a combination of kinetic studies with an injected therapeutic antibody and monitoring of endogenous antibodies, we have estimated glycation formation rates on human antibodies in healthy human subjects. Values obtained with these two approaches agree fairly well, indicating that on average 14% of antibodies have attached Glc molecules at steady state, assuming a 23-day half-life. Other published studies have measured glycation levels on human antibodies from healthy individuals (Austin et al. 1987; Kaneshige 1987; Lapolla et al. 2000) . However, results from these studies vary widely. Lapolla et al. (2000) used a MALDI, matrix-assisted desorption ionization-based MS approach to calculate glycation levels of 1-5 Glc molecules per antibody. Glycation values were determined by subtracting the mass of an antibody standard from the average mass obtained for endogenous antibody mixtures and assuming that the difference was the result of glycation. This approach appears to ignore the polyclonal nature of antibody mixtures. Normal antibody glycation values from the Kaneshige study (Kaneshige 1987) , which used two non-MS-based techniques, can be converted to an average of 0.14 Glc/antibody (14% glycated). This glycation result is in close agreement with the values listed here. Stability of the glycation products must be considered when designing testing methods. Previous reports have shown that the aldimine and even the ketoamine linkages can be reversed (Acharya and Sussman 1984; Miller et al. 2011) . Reduction with borohydride, used to generate a stable glycation product, was found to measurably increase glycation values for in vitro conditions that employed high Glc concentrations and relatively short glycation times, but not for matching in vivo conditions (6 mM Glc, pH 7.4, 37°C). Due to very slow glycation rates, analysis of in vivo samples necessitated much longer time points. This apparent discrepancy can 
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be explained by more closely examining the separate rates of aldimine and ketoamine formation. Aldimine forms quickly and reaches an equilibrium value, whereas ketoamine increases linearly with time with a rate proportional to the equilibrium aldimine concentration. As a result, at early time points (<1 day), aldimine is the major contributor to total glycation, whereas at longer times, such as those required to measure in vivo glycation, it contributes proportionately less to total glycation. In our in vivo experiments, proportionately low aldimine content (due to the prolonged time periods required) was likely obscured by the larger experimental noise level (Figure 3) . In a practical sense, the aldimine contribution to in vivo glycation could be ignored for calculation purposes.
When measuring Glc attachment to a protein like an IgG or other large protein or protein fragment, the product generated is actually a collection of products, with attachments at multiple Lys sites on the macromolecule. Each site likely has different reactivities, depending on side-chain solvent exposure and the local environment created by neighboring residues (Venkatraman et al. 2001; Zhang et al. 2008) . Because the number of Lys and the possibility that the site reactivities can vary, overall glycation levels can differ between mAbs. However, such differences were not considered in the simplified physiological model presented here. In this model, the glycation rates in vivo could be replicated fairly well in vitro by approximating the physiological pH, temperature, Glc concentration and overall Lys residue content of the serum. In serum, Glc ( 6 mM) is less abundant than the concentration of reactive Lys ( 40 mM), so competition between reactive Lys plays a major role in determining the relative glycation rates of the protein of interest. While Lys on mAbA (at 0-0.2 mg/mL in clinical samples) would be competing for Glc attachment mainly with albumin ( 40 mg/mL) and endogenous IgG ( 10 mg/mL) in the serum, the physiological model simply increases the mAbA concentration to match the overall Lys content of serum. The effect was the same, lowering relative glycation (glycation per mAbA molecule) by competition with other glycation sites from either serum proteins or other mAbA molecules. Our results demonstrate that the average Lys residue glycation rate is similar among mAbA, endogenous human IgG and HSA, even though glycation rates at individual Lys may vary widely (Quan et al. 2008; Miller et al. 2011) . This is further supported by the fact that our average (LC and HC) k 2 rate constant of 0.033 h −1 compares well with the value of 0.026 h −1 determined previously for HSA (Baynes et al. 1984) . The average in vivo glycation level of 14% means that 14% of the antibodies have a single attached Glc. Since there are several reactive Lys on the Fc, and throughout the rest of the molecule, the glycation level at any specific Lys involved in an Fc function would be a fraction of the overall glycation level. Through forced glycation conditions, we created materials much more heavily modified than would be possible in vivo in an attempt to modify all reactive sites on therapeutic antibodies to appreciable levels. Even under severe glycation conditions and with a Glc concentration over 200 times that observed in vivo (2 M Glc, pH 7.1, 23 days, 37°C), all Fc Lys were not fully modified, indicating that some residues are significantly resistant to glycation. Yet even with this degree of modification, little functional change was observed. No measurable impact to FcRn or FcγRIIIa binding was detected and very little, if any, change in protein A binding was observed. These results differ from a previous finding that glycation significantly impacted antibody binding to protein A (Dolhofer-Bliesener and Gerbitz 1990). In that study, high pH glycation incubation conditions were used, though the protein was not characterized with respect to the sites of glycation or whether other modifications existed. Instead, boronate affinity was used to determine the extent of glycation. Glycation of 40%, with presumably 40% of the molecules containing a single attached Glc, resulted in 50% loss in protein A binding. In our study, mAbs containing on average >40 Glc molecules per antibody bound protein A similar to unmodified controls.
Modifications such as glycation are often monitored during the manufacturing and storage of therapeutic antibodies. Glycation results in a change in pKa of the modified Lys that may be detected with cation exchange chromatography or isoelectric focusing (Quan et al. 2008) . In the quality-by-design paradigm, the decision to monitor and control glycation for a given therapeutic antibody would be based on its impact to safety and efficacy. An impact to target binding, for example, increases the significance of a modification. In this study, no measurable impact was found for glycation on Fc function. Glycation, as has been described here and in other studies, is a naturally occurring process in vivo, which modifies therapeutic antibodies and endogenous antibodies alike. In vitro conditions were described and demonstrated to mimic the in vivo glycation rate thereby allowing the impact of glycation to be more conveniently addressed for other therapeutic mAbs.
Materials and methods

Materials
Lysyl endopeptidase (Lys-C) was purchased from Wako Chemicals USA. Papain and Asp-N were ordered from Roche. PNGase F was from New England Biolabs. IgGZERO ® and FabRICATOR ® were obtained from QED Bioscience. Soluble human FcRn, expressed as a two-chain molecule including α2-microglubulin and a soluble α-chain including a poly-His tail, was purified in-house. Biotinylated human IgG (biotin:IgG 4.7:1) was also made in-house. Exxip F diluents were purchased from Gyros Inc. (Uppsala, Sweden) and Alexa Fluor 647 monoclonal antibody labeling kits were from Invitrogen. ZebaSpin desalting columns and Slide-A-Lyzer dialysis cassettes were from Thermo Scientific and NAP-5 columns were from GE Healthcare. All other chemicals were reagent grade or better.
Recombinant human IgG mAbs (mAbA and mAbB, each an Ig2, and mAbC, an IgG1) produced at Amgen Inc. (Thousand Oaks, CA) and expressed in CHO cells were studied (Shukla et al. 2007 ). Soluble target ligands used for affinity purification were also expressed and purified at Amgen Inc. Endogenous IgGs were isolated from the serum of healthy human donors, as described previously (Liu et al. 2009 ).
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Methods
Glycation time course experiments for method development. mAbA was incubated at 5 mg/mL with 140 mM Glc in phosphate-buffered saline (PBS) at 37°C for up to 1 week. The pH of PBS was measured at 37°C and adjusted to 7.4. Samples were collected at 0, 1, 2, 4 and 7 days. After incubating, the mAb samples were rapidly buffer exchanged by a one time 60-fold dilution with PBS and concentration to the original volume using an Amicon Ultracel centrifugal filter [Millipore, Billerica, MA, 10 kDa molecular weight cut off (MWCO)] to remove free Glc. All samples were stored ≤−70°C prior to analysis unless otherwise noted.
In vitro glycation time course experiments. Samples at 20 mg/ mL were dialyzed overnight, at 2-8°C, into 30 mM NaHCO 3 , 100 mM NaCl, pH 8, buffer containing either Glc or sorbitol at concentrations of 125, 250 or 500 mM using Slide-A-Lyzer dialysis cassettes with a molecular weight cutoff of 7 kDa. The dialyzed contents were aliquotted into micro-centrifuge tubes and incubated at 37°C, with a separate aliquot used for each time point.
In serum glycation time course experiments. mAbA at 100 mg/mL and a 5 M Glc or sorbitol stock solution were spiked into freshly collected normal donor serum, from a single individual, to final concentrations of 0.2 mg/mL and 250 mM, respectively. The total serum dilution was 5%. The samples were aliquotted into micro-centrifuge tubes and incubated at 37°C. A separate aliquot was used for each time point.
Physiological model glycation time course experiments. mAbA at 69.1 mg/mL was dialyzed overnight, at 2-8°C, into cold PBS ( pH 7.4) spiked with Glc concentrations ranging from 6 to 500 mM using Slide-A-Lyzer dialysis cassettes with a molecular weight cutoff of 7 kDa. The dialyzed contents were aliquotted into micro-centrifuge tubes and incubated at 37°C. A separate aliquot was used for each time point.
Formation of highly glycated proteins. mAbA, an IgG2, and mAbC, an IgG1, were separately dialyzed at 20 mg/mL overnight at 2-8°C against 10 mM sodium phosphate, pH 7.1, containing 2 M Glc or 2 M sorbitol and using Slide-A-Lyzer cassettes with a cutoff membrane of 7 kDa. The dialyzed contents were placed into micro-centrifuge tubes and maintained at 37°C for up to 23 days.
Sample preparation for liquid chromatography/mass spectrometry whole mass analysis. Frozen, duplicate samples from each glycation time point were thawed and rapidly buffer exchanged, at 2-8°C into 100 mM NaHCO 3 , pH 8, using 5 mL ZebaSpin desalting columns. One aliquot from each time point was immediately reduced by the addition of an equal volume of a 100-fold molar excess of NaBH 4 to protein in 4 mM NaOH and allowed to react for 1 h at room temperature, followed by neutralization with 1 N HCl for 15 min. The second aliquot from each time point was treated with an equal volume of 100 mM hydroxylamine in 100 mM NaHCO 3 , pH 8, followed by a 1 h incubation at room temperature.
Typically, the consensus N-linked glycan was removed and mAbs were reduced to constituent light (LC) and heavy chains (HC) prior to liquid chromatography/mass spectrometry (LC/MS) analysis. PNGase F was used to remove the N-linked glycans by treatment with 1 U PNGase F per 100 µg mAb for 3 h at 37°C. Samples were then brought to 6 M guanidine-HCl (GuHCl), 0.1 M Tris-HCl, pH 8, and reduced by the addition of dithiothreitol (DTT) to 20 mM followed by 30 min incubation at 37°C.
Antibody fragmentation with FabRICATOR
® . "Highly glycated" mAb (HG-mAb) samples produced by forced glycation with 2 M Glc were deglycosylated using IgGZERO ® and cleaved at a specific hinge region site (Ryan et al. 2008 ) using FabRICATOR ® (streptococcal immunoglobulin-degrading enzyme, IdeS) following vendor instructions. Deglycosylation as described here and used throughout this manuscript refers to the N-linked glycan, not the glycation. Both enzymes were obtained from Genovis, Lund, Sweden. The samples were additionally reduced by incubating with 20 mM DTT and 6 M GuHCl, pH 8, for 30 min at 37°C. These treatments fragmented the mAbs into three homogeneous, similarly sized fragments of 24 kDa each corresponding to single-chain Fc, light chain (LC) and Fd similar to that described in the preceding section. These three fragments were resolved and analyzed for total glycation by reversed phase (RP)-LC/MS in a similar fashion as that described below (Glycation Analysis by RP-high-performance liquid chromatography (HPLC)/MS) for separated LC and HC.
Glycation analysis by size-exclusion chromatography/MS. Mass analysis of intact protein was performed by size-exclusion chromatography (SEC)/MS. The analysis was performed on an Agilent 1100 HPLC system directly coupled with a Waters LCT Premier electrospray time-of-flight (TOF) mass spectrometer. An SEC column, polyhydroxyethyl aspartamide column (2.1 × 250 mm, 300 Å, Poly LC Inc., Columbia, MD, PN 202HY0503), was connected in-line for protein desalting. The column was conditioned and operated in 0.1% (v/v) formic acid in water at a flow rate of 0.1 mL/ min at room temperature ). About 4-20 µg of protein was injected for each analysis. The eluted protein was monitored at 214 nm UV light.
Deconvolution of the MS spectra was performed using Waters MassLynx software. The spectra were summed across the chromatographic peaks and deconvoluted with MaxEnt1 algorithm. An appropriate peak width was selected with an output resolution of 1.0 Da/channel; other parameters were default values for the software. The intensities of deconvoluted peaks, main peak vs modified with addition of 162 Da, were used to calculate the amount of glycation modification.
Glycation analysis by RP-HPLC/MS. The molecular weights of intact protein and the individual polypeptide chains (LC and HC) were analyzed using the above LC/MS system with a reverse-phase column Poros R1/10 column (4.6 × 50 mm). Mobile phase A was 0.1% (v/v) trifluoroacetic acid (TFA) in Glycation in vivo water; mobile phase B was 0.1% (v/v) TFA in 90% (v/v) acetonitrile/10% (v/v) water. Chromatography was performed at a flow rate of 0.2 mL/min at 75°C and monitored at UV 214 nm. The gradient was: 0 min, 30% B; 30 min, 50% B; 46 min, 90% B; then hold at 90% B for 4 min. Approximately 20 µg of protein was injected in each analysis. The MS conditions and spectra deconvolution were the same as described in the preceding section.
In vivo glycation analysis. mAbA was administrated to healthy human subjects via single 1000 mg intravenous injection. Blood samples were collected over 2 months at defined time points. After allowing time to clot, the clot was separated from serum by centrifugation (2000 × g for 15 min). Serum was stored in cryotubes at −20°C or colder until use. mAbA was purified from patient serum samples (0.5 mL) using affinity purification procedures described elsewhere (Liu, Chen et al. 2008) . The purified samples were deglycosylated and reduced prior to LC/MS analysis. Because the mAbA samples were diluted after purification (estimate 10-25 μg/mL), deglycosylation and reduction procedures were adjusted accordingly. 2.5 U of PNGase F was added to an affinity-purified mAbA sample and incubated at 37°C for 3 h. Solid GuHCl and DTT were added to achieve final concentrations of 6 M and 20 mM, respectively. The mixture was incubated at 37°C for 30 min to allow denaturation and reduction. The RP-HPLC/MS method described above was performed to quantify the glycation levels of mAbA.
Papain digestion conditions for antibodies. To generate an Fc fragment from IgG1, purified endogenous IgG at a final concentration of 1 mg/mL in 0.1 M Tris-HCl ( pH 7.6), 4 mM ethylenediaminetetraacetic acic (EDTA) and 5 mM cysteine was digested with papain (Yan et al. 2007 ). The protein to enzyme ratio was 100:1 (w/w). The reaction proceeded for 2 h at 37°C then was quenched by freezing.
FcγRIIIa-binding experiments. FcγRIIIa-binding activity was measured using a competitive AlphaLISA-binding assay format. Briefly, the recombinant soluble extracellular portion of human FcγRIIIa-(158V)-ECD-GST-His6 protein (2 nM final) was pre-incubated with PerkinElmer AlphaLISA Glutathione Acceptor Beads (10 µg/mL final), biotinylated IgG1 mAb competitor (2.5 nM final) and serially diluted antibody samples (1600 to 0.732 nM final) in wells of half-area opaque black 96-well micro-titer plates at 25°C for 24 h. PerkinElmer AlphaScreen Streptavidin-coated Donor Beads were added to each micro-titer plate well (10 µg/mL final) and incubated at 25°C for 18 h. The plates were read on a PerkinElmer EnVision plate reader equipped with an AlphaScreen detection module. The AlphaScreen relative luminescence counts were graphed against antibody concentration using Molecular Devices SoftMax Pro v. 5.3. The data were modeled using a four-parameter logistic curve fit and relative potency was calculated by comparing the constrained reference standard and sample curves.
FcRn-binding experiments. Competitive FcRn-binding experiments were carried out using a Gyrolab™ Workstation and 200 nL CDs (Honda et al. 2005; Andersson et al. 2007 ). Briefly, Alexa Fluor 647-labeled recombinant soluble human FcRn at 200 nM in Gyros Exxip F diluents titrated to pH 5.5 was pre-incubated with serial dilutions of mAb samples in 20 mM sodium acetate, 150 mM NaCl, 0.1 mg/mL bovine serum albumin (BSA) and 0.005% (w/v) Polysorbate-20, pH 5.5, then allowed to interact with the capture phase consisting of biotinylated human IgG. The capture phase was generated using 200 nL of 0.1 mg/mL biotinylated human IgG in PBS/ 0.01% (w/v) Polysorbate-20. Bound fluorescence was measured as the signal output. Alexa Fluor 647 labeling of recombinant soluble human FcRn was performed according to the manufacturer's instructions and resulted in an average incorporation of 1.5 fluorescent probes per antibody. Binding curves were derived by plotting the fluorescence signal vs sample concentration and analyzed using four-parameter fit with ExCelFit software (Gyros). All data points were generated in duplicate in each of three independent experiments.
Endoproteinase Asp-N peptide mapping of glycated products. Samples were denatured by diluting, to a final concentration of 0.5 mg/mL, into a buffer containing 6.25 M GuHCl, 20 mM Tris-HCl and 2 mM EDTA, pH 7.87. Samples were reduced by adding DTT to 10 mM and incubating for 45 min at 45°C. Subsequently, samples were carboxymethylated by adding iodoacetic acid to 20 mM and incubating for 40 min at room temperature. Samples were buffer exchanged into 50 mM potassium phosphate, pH 8.0, using NAP-5 columns. Zinc acetate was added to 0.5 mM and samples were digested with endoproteinase Asp-N (AspN) at a ratio of 1:33 for 4 h at 37°C. Finally, digested samples were quenched by the addition of 10% (v/v) formic acid to a final concentration of 0.3% (v/v).
The resultant digests were analyzed by LC/MS/MS. The LC/MS/MS system consisted of an Agilent HP1100 HPLC system connected in-line to a Thermo Scientific LTQ electrospray ion-trap mass spectrometer. A reversed-phase HPLC column (Acquity BEH130 C18, 1.7 μm, 2.1 × 50 mm, Waters Corp.) was used to separate the peptides with the column temperature at 50°C; mobile phase A: 0.1% (v/v) formic acid in water and mobile phase B: 0.09% (v/v) formic acid in 10% (v/v) water/90% (v/v) acetonitrile. The gradient (hold at 0% B for 5 min, then 0-36% B for 130 min) was performed with a flow rate of 0.2 mL/min. About 30 µg of sample was injected. The chromatogram was monitored by both UV light absorbance (set at 214 nm) and MS. Mass spectrometric detection included full scan in a positive mode, as well as datadependent ultra zoom scan and MS/MS of the most intense ion of the scan. Monoisotopic masses and charges were determined from ultra zoom scans. In-house MS software (MassAnalyzer) (Zhang 2004 ) was used to identify ions and display a sequence coverage map of the sorbitol-treated control samples. This information was used to manually search the mass lists of the Glc-treated samples for peptides having mass additions corresponding to multiples of 162 amu with retention times similar to, or eluting slightly earlier than, each parent peptide from the sorbitol-treated samples. Quantification of the average glycation level for each peptide was calculated from the glycation distribution calculated from AM Goetze et al. the MS signals, using averaged results from all available charge states. In some cases, the UV signal was used to independently assess glycation levels, with results closely matching those computed from MS signal intensities.
Protein A interaction chromatography. Antibody interactions with protein A were analyzed by protein A affinity chromatography using a pH gradient for elution as described (Pan et al. 2009 ) but with some modifications. Fifty micrograms of samples equilibrated with 20 mM Tris-HCl, 150 mM NaCl, pH 7, buffer were applied to a Poros A/20 column flowing at 2 mL/min at ambient temperature. Elution was accomplished with a linear gradient over 24 min between A buffer (20 mM Tris-HCl, 150 mM NaCl, pH 7) and 75% B buffer (5 mM acetic acid, 150 mM NaCl, pH 3.5).
Analytical SEC. Fifty-microgram sample loads were injected onto a Tosoh Bioscience G3000SWXL, 5 µm, 7.8 × 300 mm column flowing with a mobile phase of 50 mM sodium phosphate, 250 mM NaCl, pH 6.5, at 0.5 mL/min.
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